THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 113 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,081,995 | +55.5% | 125,376 | +86.5% | 0.00% | – |
| Q2 2023 | $695,831 | -69.4% | 67,230 | -67.9% | 0.00% | – |
| Q1 2023 | $2,272,121 | -52.7% | 209,412 | -51.1% | 0.00% | -100.0% |
| Q4 2022 | $4,805,728 | +32.9% | 428,318 | +20.2% | 0.00% | – |
| Q3 2022 | $3,615,000 | +81.8% | 356,482 | +62.5% | 0.00% | – |
| Q2 2022 | $1,988,000 | -16.9% | 219,418 | -12.3% | 0.00% | – |
| Q1 2022 | $2,392,000 | -61.5% | 250,179 | -55.6% | 0.00% | – |
| Q4 2021 | $6,220,000 | +53.0% | 562,922 | +2.5% | 0.00% | – |
| Q3 2021 | $4,066,000 | +344.4% | 549,419 | +772.1% | 0.00% | – |
| Q2 2021 | $915,000 | -50.3% | 63,000 | -30.2% | 0.00% | – |
| Q1 2021 | $1,841,000 | +367.3% | 90,200 | +307.0% | 0.00% | – |
| Q4 2020 | $394,000 | -74.0% | 22,162 | -78.4% | 0.00% | – |
| Q3 2020 | $1,518,000 | +33.7% | 102,706 | +89.9% | 0.00% | – |
| Q2 2020 | $1,135,000 | -14.9% | 54,087 | -6.3% | 0.00% | – |
| Q1 2020 | $1,334,000 | +84.8% | 57,702 | +55.7% | 0.00% | – |
| Q3 2019 | $722,000 | -82.9% | 37,065 | -85.7% | 0.00% | – |
| Q2 2019 | $4,234,000 | +481.6% | 259,205 | +707.5% | 0.00% | – |
| Q1 2019 | $728,000 | +50.4% | 32,100 | +69.6% | 0.00% | – |
| Q4 2018 | $484,000 | +28.7% | 18,924 | +64.6% | 0.00% | – |
| Q3 2018 | $376,000 | -73.3% | 11,500 | -77.2% | 0.00% | – |
| Q4 2017 | $1,407,000 | +93.0% | 50,459 | +136.9% | 0.00% | – |
| Q3 2017 | $729,000 | +4.1% | 21,300 | +21.3% | 0.00% | – |
| Q2 2017 | $700,000 | -32.6% | 17,564 | -37.7% | 0.00% | – |
| Q1 2017 | $1,038,000 | -64.4% | 28,200 | -69.1% | 0.00% | -100.0% |
| Q4 2016 | $2,912,000 | +727.3% | 91,317 | +841.4% | 0.00% | – |
| Q3 2016 | $352,000 | +55.8% | 9,700 | -52.8% | 0.00% | – |
| Q3 2015 | $226,000 | -35.4% | 20,563 | -23.3% | 0.00% | – |
| Q2 2015 | $350,000 | -47.3% | 26,813 | -39.8% | 0.00% | – |
| Q4 2014 | $664,000 | +26.7% | 44,531 | +171.1% | 0.00% | – |
| Q2 2014 | $524,000 | – | 16,428 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,012,226 | $60,515,510 | 8.59% |
| Irenic Capital Management LP | 2,760,948 | $23,826,981 | 6.76% |
| Newtyn Management, LLC | 1,841,560 | $15,892,663 | 3.92% |
| Weiss Asset Management LP | 7,457,060 | $64,354,428 | 3.81% |
| Park West Asset Management LLC | 1,983,251 | $17,115,456 | 1.57% |
| Baupost Group | 7,419,226 | $64,028 | 1.23% |
| Oasis Management Co Ltd. | 953,254 | $8,226,582 | 0.36% |
| Chescapmanager LLC | 287,333 | $2,479,684 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 325,985 | $2,813 | 0.24% |
| Virtus ETF Advisers LLC | 29,232 | $252,272 | 0.15% |